Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum by Yamasaki, Hidemasa
Acta Medica Okayama
Volume 30, Issue 1 1976 Article 1
FEBRUARY 1976
Pharmacology of sinomenine, an




Copyright c©1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved.
Pharmacology of sinomenine, an




The root and stem decoctions of Sinomenium acutum Rehd. et Wils. (formerly Sinomenium
diversifolius Diels, one type of Fang-chi (Chinese)) have been used as a folk remedy for neuralgia
and rheumatoid arthritis in many areas of the Far East. In Japan and China various viny plants
have been identified as Fang-chi (Boi in Japanese) since antiquity. This uncertain nomenclature
has made it difficult to evaluate the efficacy of the Fang-chi described in the classic literature.
Among traditional Fang-chi plants only Sinomeniumacutum has been demonstrated to contain the
alkaloid sinomenine, which is now known to be effective in neuralgia and rheumatic diseases.
Sinomenine is a unique plant alkaloid, as it potently releases histamine in association with degran-
ulation of tissue mast cells in mammalian tissues. This action occurs preferentially in the skin and
joint capsules. The released histamine is responsible for the dominant pharmacological actions of
sinomenine, such as vasodilatation, increased vascular permeability, acceleration of the thoracic
and peripheral lymph flow, contraction of plain muscles, increased peristalsis of the intestines,
and stimulation of gastric acid secretion. At toxic doses of sinomenine, convulsive central excita-
tion was observed in most laboratory animals. Clinical side effects encountered with high doses
of injected sinomenine or of decocted Sinomenium acutum were: injection site flare, pruritus in
the head and upper part of the body, edema around the lips and eyelids, and temporary cephalal-
gia. Most of these side effects were reduced by classical antihistamines (H1-receptor antagonists).
Daily subcutaneous injections of sinomenine for more than one week produced an analgesic ef-
fect in mice. Granulation tissue growth and adjuvant arthritis induced in rats were both inhibited
by daily injections of a small dose of sinomenine hydrochloride or histamine dihydrochloride.
These inhibitory effects were mediated through histamine H2-receptors probably on fibroblasts
(for granulation tissue growth) and on T-cells (for adjuvant arthritis), since these effects were
clearly inhibited by the H2-antagonist burimamide but not by the H1-antagonist mepyramine. The
anti-rheumatic effect on Sinomenium acutum are probably genuine and can probably be attributed
to the histamine-releasing properties of sinomenine.
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Abstract: The root and stem decoctions of Sinomenium acutum Rehd.
et Wils. (formerly Sinomenium diversifolius Diels, one type of Fang-chi
(Chinese)) have been used as a folk remedy for neuralgia and rheuma-
toid arthritis in many areas of the Far East. In Japan and China
various viny plants have been identified as Fang-chi (Hoi in Japanese)
since antiquity. This uncertain nomenclature has made it difficult to
evaluate the efficacy of the Fang-chi described in the classic literature.
Among traditional Fang-chi plants only Sinomenium acutum has been
demonstrated to contain the alkaloid sinomenine, which is now known
to be effective in neuralgia and rheumatic diseases. Sinomenine is a
unique plant alkaloid, as it potently releases histamine in association
with degranulation of tissue mast cells in mammalian tissues. This
action occurs preferentially in the skin and joint capsules. The
released histamine is responsible for the dominant pharmacological
actions of sinomenine, such as vasodilatation, increased vascular
permeability, acceleration of the thoracic and peripheral lymph flow,
contraction of plain muscles, increased peristalsis of the intestines,
and stimulation of gastric acid secretion. At toxic doses of sinomenine,
convulsive central excitation was observed in most laboratory animals.
Clinical side effects encountered with high doses of injected sinomenine
or of decocted Sinomenium acutum were: injection site flare, pruritus
in the head and upper part of the body, edema around the lips and
eyelids, and temporary cephalalgia. Most of these side effects were
reduced by classical antihistamines (HI-receptor antagonists). Daily
subcutaneous injections of sinomenine for more than one week pro-
duced an analgesic effect in mice. Granulation tissue growth and
adjuvant arthritis induced in rats were both inhibited by daily injec-
tions of a small dose of sinomenine hydrochloride or histamine dihy-
drochloride. These inhibitory effects were mediated through histamine
H~receptors probably on fibroblasts (for granulation tissue growth)
and on T-cells (for adjuvant arthritis), since these effects were clearly
inhibited by the Hz-antagonist burimamide but not by the HI-antago-
nist mepyramine. The anti-rheumatic effect of Sinomenium acutum are
probably genuine and can probably be attributed to the histamine.
releasing properties of sinomenine.
INTRODUCTION
Sinomenium acutum Rehd. et Wils. (Fam. Menispermaceae) is a wild plant
found in the warm valleys of southern Japan. This plant is hardy with twin-
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ing vines sometimes growing to a height of 20 feet. The sterns and roots are
stripped and hairless. The leaves are long-stalked, ovate or multilobed,
acuminate, usually cordate at the base, palmated to 5 to 7 divisions, and the
surfaces glabrous and brilliant (Fig. I). In summer the flower stalks grow
from the axilla of the leaves. The flowers are small, light greenish, and
organized in slender panicles. The drupes are compressed and bluish black.
The roots and stems in cross sections are whitish and are characterized by a
very distinct radiating pattern of ducts. The decocted dried roots and stems
of this plant have been used as a folk remedy for neuralgia and rheumatoid
Fig. 1. Sinomenium acutum Rehd. et Wils.
arthritis since antiquity in Japan. This plants is now included in the
Japanese pharmacopoeia under the name of Sinomeni Caulis et Rhizoma or
EDi.
The plant Fang-chi (~B), probably Sinomenium acutum, is mentioned in
the Chinese Shen Nung Pen Ts'ao (1$~*1j1r.g, "Herbal ")* (I) which was
probably written about the first century B. C., during the Western Han dynasty.
Fang-chi was recommended for the treatment of many diseases such as rheu-
matism, fevers, dropsies and pulmonary diseases in the Chin K'uei Yao Liieh
(~I.~~, "Synopsis of the Golden Chamber") written by Chang Chung-
ching (2) in the same dynasty and also in the Ming I Pieh Lu (:g~1l1j~,
... Shen Nung is the popularly ascribed mythical emperor who reigned in 2838-2698 B. C. Shen
Nung Pen Ts'ao, 3 volumes, contains descriptions of 365 kinds of herbs (1).
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"Formulas of Famous Physicians") compiled by T'ao Hung-ching ,(3) of
the Liang dynasty 502 A.D. and which is said to be the first official
pharmacopoeia in China. Among the prescriptions of Chang Chung-ching four
contained Fang-chi. The Shen Nung Pen Ts'ao (1) distinguishes between the
plant Han Fang-chi (~Itf5B) and Mu Fang-chi (*Itf5S). The former plant is
probably Sinomenium acutum, since it was prescribed' for diseases now
considered to be rheumatoid' arthritis and neuralgia, while the latter was pre-
scribed for many other diseases (2-4). In subsequent periods, varieties ,of
viny plants have been used for the original plant for medical treatment in
China and in japan, as many Menispermaceae plants closely resemble each
other in taxonomy. This has confused the identity and efficacy of Fang-chi
among traditional physicians of Chinese medicine for a long time, (5,6).
Nevertheless, it is curious that the original plant has continued to be 'Used as
a folk remedy for rheumatic diseases in many districts of japan (7).
In 1920 an alkaloid sinomenine was isolated from Sinomenium acutum (8).
This alkaloid 'has been demonstrated to be effective in relieving the pains of
rheumatoid arthritis and neuralgia in extensive clinical trials (9-12). Pharma-
cological studies on this plant have been conducted at several institutions in
japan and China. The special interest of this alkaloid is the presence of a
histamine-releasing feature that is probably important in the mechanism of
the anti-rheumatic effect. The present paper presents a brief survey of pharma-
cological studies on this alkaloid, with special reference to its anti-rheumatic
effect.
SINOMENIUM ALKALOIDS
In 1909 jujiro Honda (13), then professor of pharmacology at Okayama
Medical School, presented a paper at a meeting of ,the Okayama Medical
Association on chemical and pharmacological properties of two toxic ingre-
dients that he extracted from Sinomenium acutum, but a complete account of
this presentation does not remain. In 191 7Ishikawa (14) of Kyushu University
remarked briefly in a note that a picrotoxin-like convulsant action was found
in frogs injected in the lymph sac with a crystalline ingredient obtained from
this plant. During this early period, Taguchi and Ohta (1919)(15) conducted
investigations on this plant under Prof. Kurata Morishima, at the Pharma-
cological Department of Kyoto University. They described the circumstances
of their entering into this investigation: "February, 26, 1916, Mr. S. Masa-
gaki (probably a stranger) visited Prof. Morishima and asked the professor
earnestly to study this plant. The younger brother of the visitor suffered
from rheumatoid arthritis for many years and had difficult walking. This
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younger brother took the decoction of this plant several times, with a few days
interval. A dramatic relief occurred." Taguchi and Ohta. obtained a crystal-
line colorless ingredient from the extracts of the roots and stems of Sinomenium
acutum using the procedure of Stas and Otto. These early investigators found
that this crystalline induced convulsions in frogs. In the middle of these
studies they moved to Kitasato Institute in Tokyo, where they isolated two
kinds of convulsant alkaloid: cocculin C17H29N03 o3H20 (15) (later kukolin
C16H20N0303H20 (16, 17)) and diversin C16H:wN04 (16, 18). The form.er
was a crystalline and the latter amorphous. Ishiwari (8) at Kyoto University
continued the same line of study after the departure of Taguchi and Ohta.
He isolated from roots and stems a crystalline alkaloid and estimated the
molecular formula as C16H19NOg 0H 20, and called the compound sinomenine.




Fig. 2. Chemical structure
of sinomenine
The chemical structure of sinomenine with
the molecular formula of C19H 230 4N was estab-
lished as shown in Fig. 2 by Kondo and Ochiai
(19), and Goto and his colleagues (20) (cj. reviews
in refs. 21, 22). These studies on sinomenine
marked the first step in a series of chemical stu-
dies in Japan on the alkaloids of Menispermaceae
and other plants. Several alkaloids of Sinomenium
acutum other than sinomenine have been succes-
sively isolated and the chemical structures estab-
lished. Most of these studies were conducted
by Goto and Tomita and their colleagues. The
isolated alkaloids included disinomenine (23, 24), sinacutine (25), tuduranine
(26-28), acutumine (29), acutumidine (29), magnoflorine (30), sinoacutine
(31), michelalbine (32) and stepharine (32). The neutral substances ,B-sito-
sterol and stigmasterol were also isolated (33). The sinomenine content in the
plant is 1.0-2.0% as a base in water-extracts (34) or 1.09% as hydrochloride
(35). The percentages of other alkaloids are not known. Sinomenine has not
been isolated in other Menispermaceae plants. Pharmacological studies of
Sinomenium alkaloids have thus far been limited to sinomenine and rnagnoflo-
rine. The claimed chemical properties of diversine and parasinomenine have
not been confirmed, and the reported alkaloid isosinomenine has been shown
to be an artefact (36).
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ANTI-RHEUMATIC EFFECTS OF SINOMENINE AND SINOMENIUM ACUTUM
Decocted Sinomenium acutum has been used widely in the treatment of
rheumatic diseases in Kyushu, Shikoku, Kinki and other districts of Japan
and in Korea and Formosa with favorable reputations for remedy (7). The
usual daily dose is prepared from 8-15 g of dried cut roots and stems. The re-
markable beneficial effects of sinomenine were first reported scientifically by
Ishiwari (9) and Takaori (10) in 1921, and since then, a considerable clinical
literature (12) has confirmed their findings. Sinomenine administered subcu-
taneously (s.c.) or orally (p.o.) was remarkably effective in relieving pain,
swelling and other symptoms of acute and chronic rheumatoid arthritis and·
reduced pain in many types of neuralgia, such as sciatic neuritis, lumbalgia
and muscular rheumatism. The s.c. injections were more effective than oral
usage. Injections were usually started at 20 mg (dosages are expressed as
hydrochloride) once daily and were increased by 10-15 mg every three to
four days thereafter. Beneficial effects have been noted after two or three
injections, and most acute phase symptoms subsided after eight to nine admin-
istrations, near a daily maximum dose of 90 - 100 mg. In chronic types of
arthritis, swelling and oppressive pain in the affected joints decreased gradu-
ally, and the margins of the articular movements were increased. After the
initial injection, a relapse in pain usually occurred but on repeated injections
the periods of relief were prolonged. For oral usage, 30 - 120 mg per day in
three divided doses has been recommended.
Side effects. An itchy flare of 4-5 em in diameter appeared occasionally
around the s.c. injection site. Pruritus and facial edema occurred with large
doses of sinomenine (s.c.) or decocted Sinomenium acutum. The pruritus was
predominant in the upper parts of the body and the edema remarkable around
the eyelids and lips. Cephalalgia was encountered infrequently. These symp-
toms were temporary and abatement usually followed in about 30 min. There
is a case report of a serious side effect in a patient who was probably injected
sinomenine into the subcutaneous vein by error (37).
Edema and itching induced by sinomenine were suppressed experimentally
by the usual antihistamines (38). The usual antihistamines did not interfere
with the therapeutic effects of sinomenine on experimentally-induced arthritis
or on granulation tissue growth, as stated later in more detail. Prior to 1935
when clinical usage of sinomenine was common among physicians, antihista-
mines were not available.
PHARMACOLOGICAL PROPERTIES OF SINOMENINE
Properties inherent to the morphinoid chemical structure. Sinomenine is the
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only morphinoid base so far obtained from Menispermaceae plants. The phe-
nanthropiperidine moiety in its chemical structure is shared with morphine
and other natural opium alkaloids and with semisynthetic opiate derivatives.
Sinomenine possesses certain pharmacological properties similar to those of
morphine and related compounds. At large doses sinomenine elicits con-
vulsant-type central excitation which is also found in morphine and its
surrogates (39). The most prominent pharmacological property of sinomenine
is histamine release. This action is also present in morphine, codeine, apo-
morphine (40), ethylmorphine (41,42) and meperidine (43, 44). Meperidine
is a synthetic opioid containing r-phenyl-N-methoxypiperidine in structure like
morphine and sinomenine. One distinct difference between sinomenine and
morphine or congeners is that sinomenine may be less toxic due to the
absence of prominent central nervous actions that are inherent in morpnine,
and because the major pharmacological and probably therapeutic effects of
sinomenineare due to the potent histamine-releasing property, while for the
morphine-type analgesics, histamine release is a side effect of clinical usage.
Toxicity. Subtoxic doses of sinomenine (s.c. or p.o.) resulted in decreased
motility in mice, rats, rabbits, dogs and monkeys (8, 45). At toxic or lethal
doses (s.c. or intravenous (i.v.)) this apparent sedation was soon followed by
an increased reflex excitability or by clonic-tetanic convulsions in frogs (8),
mice (8, 45, 46), rabbits (8) and dogs (47-49). After the seizure, the animals
showed general muscular weakness and slow respiration, leading in some
cases to fatal asphyxia.
Dogs after receiving a s.c. injection of 3-5 mg/kg of sinomenine, licked
their lips, then scratched around the ear lobes, neck and jaw, where intense
itching seemed to be present. At 10 - 40 mg/kg (s.c.) pruritic giant edema
appeared in the face forming several vertical stripes in the snout. The
animals violently scratched the face and ear lobes and rubbed their bodies
against a burrowed hole. Urticaria-like macular erythemas were also visible
in the breast and abdominal skin areas. At these dose levels profuse saliva-
tion, vomiting and defecation were not uncommon. The vomiting did not
appear to be due to the direct action of sinomenine on the chemoreceptor
trigger zone (CTZ) , since direct application of 1% sinomenine onto the
caudal angle of exposed rhomboid fossa did not provoke vomiting while apo-
morphine induced vomitings (47). Increased peristalses of the intestines were
observed through the abdominal walls of dogs lying on their sides. At these
dose levels, reflex excitability increased. At doses of 60 mg/kg or more
(lethal dose), the animals laid down and were able only to stagger ataxically
when placed on their feet. Respiration was initially accelerated but soon
became weak and slow. Increased reflex excitability gradually intensified.
6
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The animals cried aloud, and then manifested trismus and convulsive move-
ments in the extremities. This was soon followed by a generalized clonic-
tetanic convulsion initiated spontaneously or with inciting events, and
occasionally culminated in opisthotonus.. With seizures at short intervals, the
animals prostrated and died in respiratory paralysis. Sinomenine injected i.v.
at 2.5 or 3 mg/kg produced these symptoms more acutely than s.c. injection
at the same dose and frequently led to death (47-49). Autopsy findings
included congestion of the mesenteric veins and the liver (47, 50, 51). Cats
receiving 10 mg/kg sinomenine s.c. scratched their heads and ear lobes and
licked or bit areas of the body. Defecation also occurred (47).
In rats, after single intraperitoneal (i.p.) injection of 50 mg/kg, vascular
dilatation or reddening was observed around the ears, mouth, snout, paws,
and scrotum (52). The animals scratched their faces with the forelegs. These
hyperemic areas were initially bright pink, changing progressively to blue as
respiration failed. Edema gradually developed in hyperemic areas. These
changes were quite obvious on visual inspection, and they were indistinguish-
able from the effects produced by an i.p. injection of egg-white, dextran
or compound 48/80. Convulsions were not observed in rats even at 300
mg/kg, i.p. (52). A single injection of sinomenine at this dose to a group
of rats reduced the histamine content of the abdominal skin by 32.5% com-
pared to the initial level. When sinomenine was injected for 6 consecutive
days starting at the initial dose of 50 mg/kg X 2 and increased daily 50 mg/
kg X 2 (total dose of 2,100 mg/kg), an 88.2% reduction in histamine content
was found in the abdominal skin. The symptoms, however, decreased gradually
after subsequent injections in spite of increased dosages (52). Rats injected
40 - 80 mg/kg daily, i.p. for 14 consecutive days showed no body weight
or food consumption effects. No changes in the blood picture or histology
were observed (45).
Mice injected with sinomenine at 300-400 mg/km, i.p. showed redden-
ing of the snout, ear lobes, feet and tail; edema was prominent in the distal
extremities. Clonic-tetanic convulsions were observed at these dosages (46,
53, 54). Skin reactions produced in rabbits; mice (46), rats (55) and dogs (48)
were reduced by appropriate doses of standard antihistamines, such as mepy-
ramine and diphenhydramine. In mice at the same dosage, these antihista-
mines did not prevent sinomenine deaths (46); Rabbits (8,53,56) and guinea
pigs (56) responded with convulsions to high doses (s.c. or i.v.) of sinomenine.
The toxic symptoms of sinomenine,' especially on the skin. resembled
those of componnd 48/80;" One difference is that at high doses sinomenine
caused convulsions while compound 48/80 resulted in severe prostration in
most examined animals (57). This suggests that the convulsive actions-of
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TABLE I. LETHAL DOSES AND MINIMUM EFFECTIVE DOSES (CONVULSION, HYPOTENSION AND
OTHER REACTIONS) OF SINOMENINE HYDROCHLORIDE
Lethal dose Minimum effective doseSpecies Route (mg/kg) Reference for indicated reaction Reference(mg/kg)
Frog Lymph 500 8 300 Convulsion 8
sac 600 58 500 Convulsion 58
650 53
Mouse s.c. 400 58 300 Convulsion 54, 59




i. v. 250 53
Rat p.o. 964t Sedation 45
i.p. 50t Marked skin reaction 52, 60
Guinea pig s. c. 350 56
Rabbit s.c. 250 8
280 58
300 53, 58
i. v. 120 58 5 Hypotension 50
150 8
i. cyst. 1.2 Convulsion 56
Dog s.c. 60 47 40-60 Convulsion 47
>60 53
i. v. =5 51 0.3 Hypotension 51
0.5 Hypotension 47
Cat s.c. 10 Convulsion 47
i. v. I Hypotension 61
Monkey p.o. 95t Sedation 45
i. v. 13.5t Prostration 45
* L D50, t without convulsion.
sinomenine may not be related to the release of histamine. Table 1 shows the
lethal doses of sinomenine for different species of laboratory animals and the
minimum effective doses for inducing convulsion and hypotension.
Cardiovascular actions. Sinomenine decreased the contraction force and
frequency of excised or perfused frog heart. Rabbit aural vessels dilated when
the perfusion fluid contained serum (47,53). Intravenous injection of sinome-
nine induced hypotension in dogs (>0.1 mg/kg, irreversible at 3 - 5 mg/kg)
(47, 48), cats (>0.1 mg/kg) (61, 62) and rabbits (>5 mg/kg) (50). In dogs
an increase occurred in the volume of the liver, intestines and extremities, and
the portal pressure rose at an early stage of hypotension (50, 51). Likewise
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in cats an increase was observed in the portal pressure and the liver volume
(61). The flow of thoracic lymph was markedly accelerated in dogs (50,51),
cats (61) and rabbits (50) in this order, and cervical lymph was increased in
dogs (51). The lymph became rich in protein content, and the blood and
lymph did not coagulate in sinomenine-shocked dogs (50, 51) and cats (61).
Tachyphylaxis of these sinomenine actions was marked, especially in dogs
(50, 51). When a small amount of sinomenine (0.05 ml of 0.1 - 0.3%
solution) was injected intracutaneously (Lc.), the human skin responded with
a triple response which was characteristic in that the wheal grew more slowly
extending more prominent pseudopod-like processes along cutaneous veins
than by histamine. A brief pain that was followed by itching of about 10 min
duration usually occurred at the injection site. Occasional cephalalgia was
encountered, due probably to the extention of cranial vascular walls.
Effects on plain muscles. Intravenous injection of sinomenine increased
the rhythmic contraction of the uterus, which culminated in contracture at
very high doses in cats and rabbits but this action was much weaker than that
of quinine (63). An increase of intestinal peristalsis has been experienced in
man after sinomenine injection or ingestion of the plant decoction. Gastric
acid secretion increased after s.c. injection of sinomenine in dogs (38).
Histamine-releasing action. After Lv. injection of sinomenine in dogs,
histamine and heparin levels elevate markedly in blood and lymph plasma, as
first reported from this laboratory (51,62,64,65). These actions of sinome-
nine were proved to be responsible for the hypotension, the rise in the portal
pressure, the increased volumes of the liver and extremities, and the inco-
agulability of blood and lymph produced by this substance; this explains the
development of tachyphylaxis in all these reactions (51). Cardiovascular
changes were completely inhibited by pretreatment with antihistamines such
as mepyramine, although the hypotension was partially inhibited (65).
In dogs i.v. injection of sinomenine depleted histamine of the skin pre-
ferentially (62, 64, 66). This response differed from compound 48/80 which
releases liver histamine more easily in dogs (62, 64, 66). After sinomenine
injection in dogs, edema or itchy erythem.a was prominent in the ear lobes,
eyelids, around the mouth and nose, and in the areolae of nipples and genito-
anal regions, where abundant histamine and mast cells are contained (49).
Joint capsule histamine was released more readily than skin histamine (49).
In tissues depleted of histamine, mast cells were disrupted at various stages,
such as granule discharge, fragmentation and disappearance of cells. In the
recovery process, a few mast cells appeared initially but gradually increased
in population and granule density. For complete recovery of the cell popula-
tion the usual period required was more than 40 days for the skin and about 2
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weeks for the joint capsules. This coincides with the recovery course of the
depleted histamine in the respective tissues (67). Occasional temporary
headaches after sinomenine injection may be due to histamine release.
Fourteen (51) to 21 percent (68) of mongrel dogs were found to be re-
fractory to both sinomenine and compound 48/80 (cross-tolerance). These
non-reactive dogs responded normally to polyvinylpyrrolidone and tween 20
and showed normal sensitivity to histamine. The incidence of non-reactors
was similar in both sexes (68).
The mechanism of histamine release by sinomenine has been studied (69 -
73, reviews 74, 75).
Analgesic and local anesthetic effect. Daily s.c. injection of histamine in
mice caused analgesia which reached maximum after 6-8 days of injection.
Similar analgesia developed under the same injection .schedule with sino-
menine. When the injection of histamine and that of sinomenine were alter-
nated daily at doses causing about the same degree of analgesia, neither agent
produced an analgesic effect. The development of analg.esia by histamine or
sinomenine was not blocked by the concurrent use of an antihistamine mepy-
ramine. The hypothermic effect of s.c. injection of histamine or sinomenine
gradually decreased on repeated daily injections. Such desensitization of the
hypothermic effect did not appear when histamine and sinomenine were in-
jected on alternate days. In mice receiving repeated injections 'of sino-
menine, the sensitivity to histamine increased as measured by the hypothermic
effect (76). The close similarity between the development of analgesia and
the desensitization of the hypothermic effect suggests the presence of histamine
receptors in the sensory nerve endings that is similar to the skin vessels,
and that histamine liberated by physical stimuli is a possible mediator of
cutaneous pain in a manner similar to its mediation of vasodilatation. Sino-
menine has a local anesthetic action as shown by i.c. injection or by instilla-
tion onto the conjunctiva (77,78).
Anti-inflammatory and anti-allergic actions. Sinomenine inhibited eggwhite
edema (52) but not carrageenin edema in rat paws (79). Daily injections to
rats of sinomenine at high dose suppressed both the increase in the weight of
croton-oil granuloma pouch and its histological inflammatory changes (60).
Canine anaphylactic shock was prevented by an Lv. or s.c. injection of sino-
menine. (48) although this effect was not evident in guinea pigs (80). A recent
report indicates that a small amount of histamine inhibits the allergic hista-
mine release from human basophils (81) .. We have shown that histamine and
also sinomenine inhibit .certain types of inflammation, as described in more
detail later.
Other pharmacological actions. Sinomenine lowered rabbit body temperature
10
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raised by heat puncture or adrenaline injection (8). Since the body temperature
is also lowered by sinomenine in normal mice (76), the hypothermic effect of
sinomenine may be due largely to the dilatation of cutaneous vessels by re-
leased histamine. Sinomenine produced hypo- and hyperglycemia in rabbits
depending upon the dosage (82). In rabbits daily injections of sinomenine
caused neutrophilia while erythrocyte count and hemoglobin concentration
remained unchanged (83). Old Chinese medical books describe the diuretic
effect of Han Fang-chi and Mu Fang-chi, but this effect has not been demon-
strated so far in sinomenine (8) and trilobine (84). The latter alkaloid is an
active principle of Cocculus trilobus D.C. which is one kind of Mu Fang-chi.
Absorption and excretion of sinomenine and the fate of released histamine.
The absorption of sinomenine was estimated in rats by the amount of urinary
histamine. Sinomenine was rapidly absorbed by s.c., Lv. and i.p. injec-
tions, but hardly absorbed by intramuscular (Lm.) injection. Peroral absorp-
tion was slower but better than by i.m. injection (85). This is consistent
with the experimental results of sinomenine on gastric acid secretion (38).
In rabbits, urinary excretion of sinomeninedepended upon the s.c. dosage
injected, but the excretion gradually decreased on repeated injections (86).
A major part of 'released histamine converts to I, 4-methylimidazole acetic
acid and imidazole acetic acid riboside; the remaining part is mostly excreted
as free histamine but a small quantity of histamine remains for several hours
in .tissues (76, 85).. The latter histamine probably has the therapeutic effects
of sinomenine or Boi, as discussed in the next paragraph.
PHARMACOLOGICAL PROPERTIES OF SINOMENINE PROBABLY
CONNECTED TO THE ANTI-RHEUMATIC EFFECT
J. Inhibitory effect of histamine and sinomenine on connective tissue growth.
A characteristic pathological feature of rheumatoid arthritis is the thick-
ening of the articular soft tissues. Synovial edema accompanied by cellular
infiltration is the first sign of disease which is followed by synovial growth,
formation of granulation tissue, accumulation of inflammatory exudates in
articular cavities, and then fibrous or bony ankylosis of the joints. Hence,
the suppression of connective tissue growth (granuloma formation) appears
therapeutically important.
To study. the effects of sinomenine and histamine on connective tissue
growth, we (87,88) placed filter-paper disks, soaked in 7% aqueous form-
aldehyde solution, in the subcutaneous tissue of each axillary and inguinai
area of male Wistar rats under sterile conditions. On the seventh day after the
operation, the granulomas including the filter-paper disks were extirpated.
11
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To intensify the pink hue of the granulation tissue, the animals were killed
by carbon monoxide poisoning.
Effects of histamine and sinomenine. Subcutaneous injections of 0.05 mg/kg
of histamine twice a day (the dose of histamine is expressed as base, but
for other drugs as salt or ester) decreased the weight of dry-defatted granu-
lomas and their contents in hydroxyproline and hexosamine. These inhibitory
effects became more marked when the dose was increased to 1 mg/kg/day.
The hydroxyproline and hexosamine values per milligram of dry-defatted
weight of gra.nuloma were not significantly altered by histamine and other
drugs tested with the exception of prednisolone at large dose. The gain in
body weight during the 7-day period from disk implantation to the removal
of granuloma was increasingly reduced by increasing dose of histamine, but
this effect attained statistical significance only at doses higher than 1 mg/kg/
day. Thymus weight was not affected at any dose.
The effects of sinomenine were tested at two different doses. In rats
given large doses of sinomenine before disk implantation and during granu-
loma growth period*, the histamine content of the abdominal skin at the time
of granuloma removal was markedly decreased to a level of 6.7 ± 0.8 pg/g
wet wt. of tissue (mean ± S. E. M., N =6) compared to 23.1 ± 0.8 pg/g (N
=4) in the control group. The formation of granuloma was inhibited by
55.7% in terms of weight by this treatment. When a relatively small dose
of sinomenine (15 mg/kg twice a day) was administered from the implantation
day to one day before the removal of granulomas without pretreatment of
sinomenine, the histamine content of abdominal skin was 25.3 ± 3.6 pg/g
(N =4) on the day of granuloma extirpation. In spite of the absence of an
effect on skin histamine content, this small dose of sinomenine inhibited
granuloma formation at the same rate as a larger dose.
Aminoguanidine bicarbonate, a potent histaminase inhibitor, produced a
marked inhibitory effect on granuloma formation at a s.c. dose of 10 mg/
kg/day. The inhibition of granuloma growth by 0.5 mg/kg/day of predni-
solone (i.m.) was less marked than 0.1 mg/kg/day of histamine (s.c.). This
dose of prednisolone, however, strikingly inhibited the growth of rats and
caused a decrease in thymus weight. Phenylbutazone was ineffective at a
daily dose of 30 mg/kg.
Effects of burimamide and mepyramine. Burimamide is known to speci-
fically block histamine H 2-receptors and to antagonize responses to histamine,
* The rats were pretreated before the disk implantation by i. p. injection of sinomenine for
6 days: on the first day 50 mg/kg X 2, increasing by 50 mg/kg X 2 daily, until a final dose of
300 mg/kgx2 (total dose=2,IOO mg/kg). From the implantation day, 300 mg/kg was injected
once daily.
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such as stimulation of gastric acid secretion (89). When 5 mg/kg of burima-
mide was injected s.c. 30 min prior to the injection of 0.05 mg/kg of
histamine, this compound clearly antagonized the inhibitory effect of histamine
on the formation of granuloma and even enhanced its growth as revealed by
the increased granuloma weight and hydroxyproline and hexosamine contents.
Burimamide also blocked the inhibitory effect of sinomenine and aminoguani-
dine. Mepyramine, the classical antagonist of histamine H 1-receptors (89),
was ineffective in blocking the inhibitory effect of histamine at a similar dosage
as that used for burimamide. The hydroxyproline and hexosamine values per
milligram of dry-defatted weight of granuloma were not markedly altered
by histamine antagonists.
Histological studies. In granulomas obtained from rats treated with 0.05
mg/kg of histamine twice a day, tissue layers of densely populated fibroblasts
were narrower than those of control animals. The formation of blood vessels
in the granulation tissue appeared to be also poor in the treated rats. These
morphological effects were entirely or largely counteracted when burimamide
was injected concurrently with histamine. In sinomenine- and aminoguanidine-
treated rats the morphological pattern of granuloma formation was similar to
that observed in histamine-treated rats.
Comment. It has been shown that activation of H 2-receptors leads to an
increase in the level of cyclic AMP in lymphocytes (90,91), leukocytes (81),
gastric tissue (92) and cardiac tissue (93). It is also known that the growth
of cultured fibroblasts is inhibited by the increase in intracellular level of
cyclic AMP (94). Therefore, the histamine inhibition of the granuloma growth
may be induced by a rise in the cyclic AMP level of fibroblasts through the
activation of H 2-receptors. We have recently observed an increase in the
cyclic AMP content of granulomas in rats after a s.c. injection of histamine
(95).
2. Inhibitory effect of histamine and sinomenine on adjuvant arthritis
The rat adjuvant arthritis shows a close similarity to the human rheu-
matoid arthritis in clinical signs. A dose of 0.05 ml of adjuvant mixture
containing 0.25 mg of finely-ground killed Micobacterium tuberculosis was
administered i.d. under the volar surface of the left hind paw of male inbred
Sprague-Dawley rats. The volume of each hind paw was measured prior to
adjuvant injection and once daily thereafter.
Effects of histamine and sinomenine. Sinomenine was injected i.p. at a
dose of 15 mg/kg twice daily from the day of adjuvant injection (day 0).
Sinomenine did not inhibit the primary inflammation in the adjuvant-injected
paw which reached maximum on day 5 or day 6, but significantly suppressed
swelling of the secondary inflammation which appeared in the adjuvant-
13
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Fig. 3. Effect of histamine on adjuvant-induced lesions in the rat hind pa w.
Histamine was injected at 5 mg/kg, s. c., twice a day from day 5 to day 10. The
control rat received 0.9% saline. Roentgenographs were taken on day 25. a, Saline-
treated rat; b, histamine-treated rat. The adjuvant-injected paw is on the left in
both figures (97).
noninjected paw at day 10 or later. Histamine administered s.c. at a dose
of 5 mg/kg twice daily also had a similar inhibitory effect. In the vehicle-
treated control group, marked swelling and ankylosis of tarsal and other
pedal joints were visible. Fusion of joints and destruction of bones and carti-
lages were observed in roentgenograms. These changes were more marked in
the adjuvant-injected paw but were also observed in the adjuvant-noninjected
paw. In groups treated with sinomenine or histamine, these radiological
changes were also clearly inhibited (96, 97) (Fig. 3).
Histamine markedly suppressed the appearance of the secondary inflam-
mation of adjuvant arthritis when injected for 6 consecutive days from day 5
14
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to day 10. Histamine injection prior to or after this critical 6-day period
produced no significant inhibition of the secondary inflammatory response.
Histamine had no suppressive effect on the secondary lesion when administered
after the establishment of the lesion. Therefore, the histamine effect on the
secondary lesions appears to be based on a different mechanism from the
usual anti-inflammatory drugs.
Effects of burimamide andmepyramine. When burimamide at 5 mgjkg
was injected simultaneously with histamine of the same dosage, a complete
blockage of histamine inhibition was 'found in the secondary inflammatory
response and in histological and radiological examinations. Mepyramine at
the same dosage showed no such blocking effect.
Comment. Rat adjuvant arthritis has been reported as being caused by
cell-mediated immunity, mainly from evidence of the passive transfer of this
disease with living lymph node cells (98). The most effective period of
histamine administration to prevent the appearance of the secondary lesion of
adjuvant arthritis coincides closely with the effective period reported for some
immunosuppressants (99, 100).
Since the inhibitory effect of histamine on adjuvant arthritis is not an-
tagonized by mepyamine and is completely blocked by burimamide, the
histamine effect appears to be mediated through H 2-receptors. Histamine
causes an increase in the cyclic AMP 'level of lymphocytes through the acti-
vation of H 2-receptors (91). In connection with this effect, histamine inhibits
responses to antigen-stimulation, such as the proliferation and differentiation
of lymphoid cells, immunoglobulin production and the cytotoxic activity of
lymphocytes (101). Qur findings together with the histamine effects on
lymphoid cells described by others (99) suggest that the suppressive effect of
histamine in adjuvant arthritis may be related to the inhibition of T-Iym-
phocyte proliferation. The catecholamine release by histamine is blocked by
HI-receptor antagonists (102). Therefore, the catecholamines released by
histamine do not seem to play an important role in the histamine inhibition of
adjuvant arthritis. .
From the inhibitory effects of histamine on adjuvant arthritis and granu-
lation-tissue growth, it appears likely that the antirheumatic properties of
sinomenine is mediated through histamine released from mast cells.
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